Key result
Dedicated Trilogy valve cuts mortality risk ~60% vs non-dedicated valves in native aortic regurgitation.
Why the study?
Until recently, no standard of care existed for patients with symptomatic native aortic regurgitation (AR) unsuitable for surgery. TAVI had been explored using off-label, non-dedicated valves designed for aortic stenosis, whereas the ALIGN-AR trial evaluated the dedicated Trilogy valve.
Does transcatheter aortic valve implantation with a dedicated Trilogy valve improve overall survival compared to non-dedicated transcatheter valves in patients with symptomatic native aortic regurgitation?
Meta-Analysis (n=1,359)
Does transcatheter aortic valve implantation with a dedicated Trilogy valve improve overall survival compared to non-dedicated transcatheter valves in patients with symptomatic native aortic regurgitation?
In patients with native aortic regurgitation undergoing TAVI, the dedicated Trilogy valve demonstrates a significant survival advantage over off-label non-dedicated valves, providing approximately 1 month of additional survival within the first year.
Answers are grounded in this paper and cite their sources.
May support dedicated Trilogy valve in inoperable native AR; leaves open randomized confirmation before practice change.
BACKGROUND: Until recently, no standard of care has been established for patients with symptomatic native aortic regurgitation (AR) who are unsuitable for surgery. Transcatheter aortic valve implantation (TAVI) has been explored in this setting using off-label, non-dedicated valves originally designed for aortic stenosis. The recent ALIGN-AR trial evaluated the Trilogy valve, a dedicated transcatheter device specifically designed for native AR. METHODS: We performed an indirect comparison between the overall survival (OS) reported for the Trilogy valve in ALIGN-AR and OS from seven single-arm studies using non-dedicated valves. Individual patient data were reconstructed from published Kaplan-Meier curves using the IPDfromKM method. To ensure homogeneity, the follow-up period for the survival analysis was truncated at 24 months. Survival was analyzed using both hazard ratios (HR) and restricted mean survival time (RMST). RESULTS: The analysis included 492 patients treated with the Trilogy valve and 867 treated with non-dedicated valves. OS was significantly improved with the Trilogy valve (HR 0.399; 95% CI 0.275-0.578; p = 0.0000011). RMST at 12 months was 11.4 months for the Trilogy valve versus 10.4 months for non-dedicated valves, corresponding to an OS gain of 1.0 months (95% CI 0.72-1.32) over the first year. CONCLUSIONS: In patients with native AR undergoing TAVI, use of the dedicated Trilogy valve was associated with a highly significant survival advantage compared with non-dedicated devices, corresponding to an approximate 1-month gain in OS during the first 12 months after implantation.
No takes yet. Share an insight, caveat, or question.
Messori et al. (2026) conducted a meta-analysis in Symptomatic native aortic regurgitation (n=1,359). Trilogy dedicated transcatheter valve vs. Non-dedicated transcatheter valves was evaluated on Overall survival (OS) (HR 0.399, 95% CI 0.275-0.578, p=0.0000011). The dedicated Trilogy valve improved overall survival vs non-dedicated valves in native aortic regurgitation.
Synapse has enriched 10 related papers. Consider them for comparative context: